SNY - Sanofi's Sarclisa gets accepted for FDA priority review for treatment of multiple myeloma
2024-05-27 02:50:31 ET
More on Sanofi
- Sanofi Q1: Wait And See For Now (Downgrade)
- Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade)
- Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results
- Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M